Phase 1 Study of ATR-002

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 24, 2019

Primary Completion Date

August 26, 2019

Study Completion Date

August 26, 2019

Conditions
Influenza
Interventions
DRUG

ATR-002 MEK Inhibitor

Drug ATR-002 administered as film-coated tablet via oral route

DRUG

Placebo oral tablet

Placebo film-coated tablet administered via oral route

Trial Locations (1)

2020

SGS Life Sciences, Clinical Pharmacology Unit Antwerpen, Antwerp

Sponsors
All Listed Sponsors
collaborator

SGS Life Sciences, a division of SGS Belgium NV

OTHER

lead

Atriva Therapeutics GmbH

INDUSTRY

NCT04385420 - Phase 1 Study of ATR-002 | Biotech Hunter | Biotech Hunter